Romidepsin-d7

Romidepsin-d7 (FK 228-d7) is deuterium labeled Romidepsin. Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively[1]. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis[2].

Product Specifications

Product Name Alternative

FK 228-d7; FR 901228-d7; NSC 630176-d7

UNSPSC

12352005

Target

Apoptosis; HDAC; Isotope-Labeled Compounds

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

C/C=C(NC([C@@H](CSSCC/C=C/[C@@H](O1)CC2=O)NC([C@@H](C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])N2)=O)=O)/C(N[C@@H](C(C)C)C1=O)=O

Molecular Formula

C24H29D7N4O6S2

Molecular Weight

547.74

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Furumai R, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002 Sep 1;62 (17) :4916-21.|[3]Sun WJ, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017 Mar 1;127:90-100.